A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: Results of a planned safety analysis

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 8, 2012, Pages 1413-1419

  Mahner, Sven ^a   Oskay Özcelik, Gülten ^b   Heidrich Lorsbach, Elke ^c   Fuxius, Stefan ^d   Sommer, Harald ^e   Klare, Peter ^f   Belau, Antje ^g   Ruhmland, Birgit ^h   Heuser, Thomas ⁱ   Kölbl, Heinz ^j   Markmann, Susanne ^k   Sehouli, Jalid ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ALCEDIS GMBH   (Germany)

^d Private Practice Oncology   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f Private Practice Gynecology and Gynecologic Oncology   (Germany)

^g UNIVERSITY OF GREIFSWALD   (Germany)

^h Private Practice   (Germany)

ⁱ Klinikum Herford   (Germany)

^j JOHANNES GUTENBERG UNIVERSITY   (Germany)

^k UNIVERSITY OF ROSTOCK   (Germany)

more..

Author keywords

Chemotherapy; Elderly; Ovarian cancer; Patient preference; Safety; Treosulfan

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM COMPLEX; TOPOTECAN; TREOSULFAN;

ABDOMINAL PAIN; ACUTE DISEASE; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTHRITIS; ARTICLE; ASCITES; BACKACHE; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; COMMON COLD; COMORBIDITY; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; CONVULSION; DIAPHORESIS; DIARRHEA; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; DYSURIA; EDEMA; EXPLORATORY RESEARCH; FATIGUE; FEMALE; GASTRITIS; HEARING LOSS; HOARSENESS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDRONEPHROSIS; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; ILEUS; INCONTINENCE; INFECTION; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OVARY CARCINOMA; PAIN; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RHINOPHARYNGITIS; SIDE EFFECT; SKIN TOXICITY; SLEEP DISORDER; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERTIGO; VIRUS INFECTION; WEIGHT REDUCTION; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ALOPECIA; ANEMIA; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CONSTIPATION; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; LEUKOPENIA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE; TREATMENT OUTCOME;

EID: 84864354029     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1221-3     Document Type: Article

References (18)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) (2010) SEER Cancer Statistics Review, 1975-2007. National Cancer Institute, Bethesda. http://seer. cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010
2. Breidenbach M, Rein DT, Schöndorf T, Schmidt T, König E, Valter M, Kurbacher CM (2003) Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer. Anticancer Drugs 14:341-346 (Pubitemid 36683744)
3. Gondos A, Holleczek B, Arndt V, Stegmaier C, Ziegler H, Brenner H (2007) Trends in population-based cancer survival in Germany; to what extent does progress reach older patients? Ann Oncol 18:1253-1259 (Pubitemid 47244374)
4. Gropp M, Meier W, Hepp H (1998) Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 71:94-98 (Pubitemid 28492400)
5. Harter P, du Bois A, Schade-Brittinger C, Burges A, Wollschlaeger K, Gropp M, Schmalfeldt B, Huober J, Staehle A, Pfisterer J (2005) Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 16:1801-1805 (Pubitemid 41631243)
6. Hilger RA, Jacek G, Oberhoff C, Kredtke S, Baumgart J, Seeber S, Scheulen ME (2000) Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Cancer Chemother Pharmacol 45:483-488 (Pubitemid 30316909)
7. Keldsen N, Madsen EL, Havsteen H, Kamby C, Laursen L, Sandberg E (1998) Oral treosulfan as second-line treatment in platinumresistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group. Gynecol Oncol 69:100-110
8. Köpf-Maier P, Sass G (1996) Antitumor activity of treosulfan in human lung carcinomas. Cancer Chemother Pharmacol 37:211-221
9. Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J (2009) Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/ paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 114:199-205
10. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM (2010) Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 28(19):3107-3114
11. Oleitan A, Mocroft A, Jacobs I (2000) Patterns in the incidence of age-related ovarian cancer in South East England 1967-1996. BJOG 107:1094-1096
12. Pallis AG, Fortpied C, Wedding U, Van Nes MC, Penninckx B, Ring A, Lacombe D, Monfardini S, Scalliet P, Wildiers H (2010a) EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 46:1502-1513
13. Pallis AG, Wedding U, Lacombe D, Soubeyran P, Wildiers H (2010b) Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know? Eur J Cancer 46:1019-1025
14. Pignata S, Vermorken JB (2004) Ovarian cancer in the elderly. Crit Rev Oncol Hematol 49:77-86 (Pubitemid 38084823)
15. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010) Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28(20):3323-3329
16. Reed NS, Poole CJ, Coleman R, Parkin D, Graham JD, Kaye SB, Ostrowski J, Duncan I, Paul J, Hay A (2006) A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish gynaecological cancer trials group (SGCTG). Eur J Cancer 42:179-185 (Pubitemid 43083487)
17. Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W (2008) Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26:3176-3182
18. Uziely B, Groshen S, Jeffers S, Morris M, Russell C, Roman L, Muderspach L, Muggia F (1994) Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. Ann Oncol 5:8827-8833